Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues.
Cancer management
Metastatic disease
Skeletal-related event
Thyroid cancer
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
05
2020
accepted:
24
07
2020
pubmed:
4
8
2020
medline:
12
10
2021
entrez:
4
8
2020
Statut:
ppublish
Résumé
Bone represents the second most common site of distant metastases in differentiated thyroid cancer (DTC). The clinical course of DTC patients with bone metastases (BM) is quite heterogeneous, but generally associated with low survival rates. Skeletal-related events might be a serious complication of BM, resulting in high morbidity and impaired quality of life. To achieve disease control and symptoms relief, multimodal treatment is generally required: radioiodine therapy, local procedures-including surgery, radiotherapy and percutaneous techniques-and systemic therapies, such as kinase inhibitors and antiresorptive drugs. The management of DTC with BM is challenging: a careful evaluation and a personalized approach are essential to improve patients' outcomes. To date, prospective studies focusing on the main clinical aspects of DTC with BM are scarce; available analyses mainly include cohorts assembled over multiple decades, small samples sizes and data about BM not always separated from those regarding other distant metastases. The aim of this review is to summarize the most recent evidences and the unsolved questions regarding BM in DTC, analyzing several key issues: pathophysiology, prognostic factors, role of anatomic and functional imaging, and clinical management.
Identifiants
pubmed: 32743746
doi: 10.1007/s40618-020-01374-7
pii: 10.1007/s40618-020-01374-7
pmc: PMC7878269
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-419Références
NIH. National Cancer Institute. SEER (Survelliance, Epidemiology, and End Results Program) cancer statistics. Available from https://seer.cancer.gov/statfacts/html/thyro.html . Accessed 30 Mar 2020
Hodak SP, Burman KD (2006) Thyroid carcinoma. metastases to bone. In: Wartofsky L, Van Nostrand D (eds) Thyroid cancer: a comprehensive guide to clinical management, 2nd edn. Humana, New Jersey, pp 497–508
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91(8):2892–2899
pubmed: 16684830
Muresan MM, Olivier P, Leclère J, Sirveaux F, Brunaud L, Klein M, Zarnegar R, Weryha G (2008) Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 15(1):37–49
pubmed: 18310274
Iñiguez-Ariza NM, Bible KC, Clarke BL (2020) Bone metastases in thyroid cancer. J Bone Oncol 21:100282
pubmed: 32154098
pmcid: 7058902
Pal P, Singh B, Kane S, Chaturvedi P (2018) Bone metastases in follicular carcinoma of thyroid. Indian J Otolaryngol Head Neck Surg 70(1):10–14
pubmed: 29456936
Osorio M, Moubayed SP, Su H, Urken ML (2017) Systematic review of site distribution of bone metastases in differentiated thyroid cancer. Head Neck 39(4):812–818
pubmed: 28079945
Farooki A, Leung V, Tala H, Tuttle RM (2012) Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 97(7):2433–2439
pubmed: 22564664
Choksi P, Papaleontiou M, Guo C, Worden F, Banerjee M, Haymart M (2017) Skeletal complications and mortality in thyroid cancer: a population-based study. J Clin Endocrinol Metab 102(4):1254–1260
pubmed: 28324052
pmcid: 5460727
Wexler JA, Sharretts J (2007) Thyroid and bone. Endocrinol Metab Clin North Am 36(3):673–705
pubmed: 17673124
Cabanillas ME, McFadden DG, Durante C (2016) Thyroid cancer. Lancet 388(10061):2783–2795
pubmed: 27240885
Robenshtok E, Farooki A, Grewal RK, Tuttle RM (2014) Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. Endocrine 47(1):266–272
pubmed: 24366637
Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ (2000) Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10(3):261–268
pubmed: 10779141
Orita Y, Sugitani I, Matsuura M, Ushijima M, Tsukahara K, Fujimoto Y, Kawabata K (2010) Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery 147(3):424–431
pubmed: 20176243
Slook O, Levy S, Slutzky-Shraga I, Tsvetov G, Robenshtok E, Shimon I, Benbassat C, Hirsch D (2019) Long-term outcomes and prognostic factors in patients with differentiated thyroid carcinoma and bone metastases. Endocr Pract 25(5):427–437
pubmed: 30657361
Choi YM, Kim WG, Kwon H, Jeon MJ, Lee JJ, Ryu JS, Hong EG, Kim TY, Shong YK, Kim WB (2016) Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. Eur J Endocrinol 175(3):165–172
pubmed: 27272238
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R (2018) Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine 59(1):90–101
pubmed: 29110129
Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT (2009) Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10(6):606–614
pubmed: 19482249
Talbot JN, Paycha F, Balogova S (2011) Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging 55(4):374–410
pubmed: 21738113
Buhmann Kirchhoff S, Becker C, Duerr HR, Reiser M, Baur-Melnyk A (2009) Detection of osseous metastases of the spine: comparison of high resolution multi-detector-CT with MRI. Eur J Radiol 69(3):567–573
pubmed: 18191356
Jehn CF, Diel IJ, Overkamp F, Kurth A, Schaefer R, Miller K, Lüftner D (2016) Management of metastatic bone disease algorithms for diagnostics and treatment. Anticancer Res 36(6):2631–2637
pubmed: 27272771
Soliman M, Taunk NK, Simons RE, Osborne JR, Kim MM, Szerlip NJ, Spratt DE (2017) Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. Neurosurg Focus 42(1):E5
pubmed: 28041315
Stecco A, Trisoglio A, Soligo E, Berardo S, Sukhovei L, Carriero A (2018) Whole-body MRI with diffusion-weighted imaging in bone metastases: a narrative review. Diagnostics (Basel) 8(3):45
Sakurai Y, Kawai H, Iwano S, Ito S, Ogawa H, Naganawa S (2013) Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. J Med Imaging Radiat Oncol 57(3):297–305
pubmed: 23721138
Nagamachi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, Futami S, Arita H, Kuroki M, Nakada H, Uchino N, Tamura S, Kawai K (2011) Comparison of diagnostic and prognostic capabilities of
pubmed: 21786097
Mossa-Basha M, Gerszten PC, Myrehaug S, Mayr NA, Yuh WT, Jabehdar Maralani P, Sahgal A, Lo SS (2019) Spinal metastasis: diagnosis, management and follow-up. Br J Radiol 92(1103):20190211
pubmed: 31322920
pmcid: 6849675
Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K, Teytelboym OM (2019) Medullary thyroid carcinoma: an update on imaging. J Thyroid Res 2019:1893047
pubmed: 31360432
pmcid: 6642782
Qiu ZL, Xue YL, Song HJ, Luo QY (2012) Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun 33(12):1232–1242
pubmed: 23111353
Hassan FU, Mohan HK (2015) Clinical utility of SPECT/CT imaging post-radioiodine therapy: does it enhance patient management in thyroid cancer? Eur Thyroid J 4(4):239–245
pubmed: 26835427
pmcid: 4716421
Wang H, Fu HL, Li JN, Zou RJ, Gu ZH, Wu JC (2009) The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clin Imaging 33(1):49–54
pubmed: 19135930
Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, Kang SR, Kim DY, Song HC, Bom HS, Min JJ (2011) Comparison of
pubmed: 21505897
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the AMERICAN Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133
pubmed: 26462967
pmcid: 4739132
Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S (2015) Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 25(4):437–444
pubmed: 25633259
Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M (2009) Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94(4):1310–1316
pubmed: 19158200
Chang CY, Gill CM, Joseph Simeone F, Taneja AK, Huang AJ, Torriani M, Bredella MA (2016) Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases. Acta Radiol 57(1):58–65
pubmed: 25533313
Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, Abe S, Nakano S, Nishino M, Ishigaki T, Naganawa S (2007) Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 48(6):889–895
pubmed: 17504877
Ota N, Kato K, Iwano S, Ito S, Abe S, Fujita N, Yamashiro K, Yamamoto S, Naganawa S (2014) Comparison of
pubmed: 24297809
pmcid: 4064540
Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE (2016) Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leuk Lymphoma 57(5):1114–1121
pubmed: 26690712
pmcid: 5576169
Vaz S, Usmani S, Gnanasegaran G, Van den Wyngaert T (2019) Molecular imaging of bone metastases using bone-targeted tracers. Q J Nucl Med Mol Imaging 63(2):112–128
pubmed: 31286752
Almeida LS, Araújo MC, Zantut-Wittmann DE, Assumpção LV, Souza TF, Silva CM, Argenton JL, Santos AO, Mengatti J, Ramos CD, Etchebehere EC (2018) Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study. Nucl Med Commun 39(5):441–450
pubmed: 29543624
Parihar AS, Mittal BR, Kumar R, Shukla J, Bhattacharya A (2020) 68Ga-DOTA-RGD2 positron emission tomography/computed tomography in radioiodine-refractory thyroid cancer: prospective comparison of diagnostic accuracy with 18F-FDG positron emission tomography/computed tomography and evaluation toward potential theranostics. Thyroid. https://doi.org/10.1089/thy.2019.0450 (Epub ahead of print)
doi: 10.1089/thy.2019.0450
pubmed: 31870227
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger M, DECISION investigators (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319–328
pubmed: 24768112
pmcid: 4366116
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 372(7):621–630
pubmed: 25671254
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
pubmed: 19097774
Costelloe CM, Chuang HH, Madewell JE, Ueno NT (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1:80–92
pubmed: 20842228
pmcid: 2938069
Castello A, Lopci E (2019) Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2. Q J Nucl Med Mol Imaging 63(2):150–158
pubmed: 31286751
Wang C, Zhang X, Yang X, Li H, Cui R, Guan W, Li X, Zhu Z, Lin Y (2018) PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer. Endocr Relat Cancer 25(6):653–663
pubmed: 29618578
Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M, Durante C, Elisei R, Fadda G, Frasoldati A, Fugazzola L, Guglielmi R, Lombardi CP, Miccoli P, Papini E, Pellegriti G, Pezzullo L, Pontecorvi A, Salvatori M, Seregni E, Vitti P (2018) Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Invest 41(7):849–876
pubmed: 29729004
National Comprehensive Cancer network (NCCN) Clinical practice guidelines in oncology. Thyroid carcinoma. Version 1.2019. Available from https://nccn.org . Accessed 18 Mar 2020
Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, Smit J (2019) 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J 8(5):227–245
pubmed: 31768334
pmcid: 6873012
Wu D, Gomes Lima CJ, Moreau SL, Kulkarni K, Zeymo A, Burman KD, Wartofsky L, Van Nostrand D (2019) improved survival after multimodal approach with 131I treatment in patients with bone metastases secondary to differentiated thyroid cancer. Thyroid 29(7):971–978
pubmed: 31017051
Qiu ZL, Song HJ, Xu YH, Luo QY (2011) Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 96(10):3078–3086
pubmed: 21795449
Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37(4):598–605
pubmed: 8691248
Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86(4):1568–1573
pubmed: 11297585
Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, Wartofsky L (2011) Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab 96(10):3217–3225
pubmed: 21849530
pmcid: 7372577
Finessi M, Liberini V, Deandreis D (2019) Major limits of dosimetrically determined activities in advanced differentiated thyroid carcinoma. Q J Nucl Med Mol Imaging 63(3):258–266
pubmed: 31560183
Verburg FA, Flux G, Giovanella L, van Nostrand D, Muylle K, Luster M (2020) Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. Eur J Nucl Med Mol Imaging 47(1):78–83
pubmed: 31616967
Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle RM (2017) Comparison of empiric versus whole-body/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med 58(5):717–722
pubmed: 27738010
Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, Backes WH, Mottaghy FM, Jentzen W (2016) Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. J Nucl Med 57(7):1027–1032
pubmed: 26917706
Jentzen W, Hoppenbrouwers J, Van Leeuwen P, Van Der Velden D, Van De Kolk R, Poeppel TD, Nagarajah J, Brandau W, Bockisch A, Rosenbaum-Krumme S (2014) Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med 55(11):1759–1765
pubmed: 25332440
Jentzen W, Verschure F, Van Zon A, Van De Kolk R, Wierts R, Schmitz J, Bockisch A, Binse I (2016) 124I PET assessment of response of bone metastases to initial radioiodine treatment of differentiated thyroid cancer. J Nucl Med 57(10):1499–1504
pubmed: 27199362
Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, Dillehay G, Draganescu C, Flux G, Führer D, Giovanella L, Greenspan B, Luster M, Muylle K, Smit JWA, Van Nostrand D, Verburg FA, Hegedüs L (2019) Controversies, Consensus, and Collaboration in the use of 131I therapy in differentiated thyroid cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29(4):461–470
pubmed: 30900516
Choudhury PS, Gupta M (2018) Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol 91(1091):20180136
pubmed: 30260232
pmcid: 6475953
Kushchayeva YS, Kushchayev SV, Wexler JA, Carroll NM, Preul MC, Teytelboym OM, Sonntag VK, Van Nostrand D, Burman KD, Boyle LM (2014) Current treatment modalities for spinal metastases secondary to thyroid carcinoma. Thyroid 24(10):1443–1455
pubmed: 24827757
Wexler JA (2011) Approach to the thyroid cancer patient with bone metastases. J Clin Endocrinol Metab 96(8):2296–2307
pubmed: 21816796
Satcher RL, Lin P, Harun N, Feng L, Moon BS, Lewis VO (2012) Surgical management of appendicular skeletal metastases in thyroid carcinoma. Int J Surg Oncol 2012:417086
pubmed: 23304478
pmcid: 3530792
Kato S, Murakami H, Demura S, Fujimaki Y, Yoshioka K, Yokogawa N, Tsuchiya H (2016) The impact of complete surgical resection of spinal metastases on the survival of patients with thyroid cancer. Cancer Med 5(9):2343–2349
pubmed: 27431619
pmcid: 5055174
Demura S, Kawahara N, Murakami H, Abdel-Wanis ME, Kato S, Yoshioka K, Tomita K, Tsuchiya H (2011) Total en bloc spondilectomy for spinal metastasis in thyroid carcinoma. J Neurosurg Spine 14(2):172–176
pubmed: 21184643
Zhang D, Yin H, Wu Z, Yang X, Liu T, Xiao J (2013) Surgery and survival outcomes of 22 patients with epidural spinal cord compression caused by thyroid tumor spinal metastases. Eur Spine J 22(3):569–576
pubmed: 23076644
Gerszten PC, Mendel E, Yamada Y (2009) Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications and outcomes? Spine (Phila Pa 1976) 34(22 Suppl):S78–92
Simpson WJ (1990) Radioiodine and radiotherapy in the management of thyroid cancers. Otolaryngol Clin North Am 23(3):509–521
pubmed: 1694984
Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M (2005) Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97(11):798–804
pubmed: 15928300
Foro Arnalot P, Fontanals AV, Galcerán JC, Lynd F, Latiesas XS, de Dios NR, Castillejo AR, Bassols ML, Galán JL, Conejo IM, López MA (2008) Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 89(2):150–155
pubmed: 18556080
Gerszten PC, Burton SA, Ozhasglu C, Welch WC (2007) Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 32(2):193–199
Bernstein MB, Chang EL, Amini B, Pan H, Cabanillas M, Wang XA, Allen PK, Rhines LD, Tatsui C, Li J, Brown PD, Ghia AJ (2016) Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of phase I/II trials. Thyroid 26(9):1269–1275
pubmed: 27334245
Ishigaki T, Uruno T, Sugino K, Masaki C, Akaishi J, Hames KY, Suzuki A, Tomoda C, Matsuzu K, Ohkuwa K, Kitagawa W, Nagahama M, Miyazaki S, Ito K (2019) Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer. J Radiat Res 60(6):831–836
pubmed: 31423531
pmcid: 6873619
Harada Y, Miyazaki S (2019) Multisession CyberKnife radiosurgery for advanced follicular thyroid cancer. Cureus 11(11):e6159
pubmed: 31890367
pmcid: 6913948
Hariri O, Takayanagi A, Lischalk J, Desai K, Florence TJ, Yazdian P, Chang SD, Vrionis F, Adler JR, Quadri SA, Desai A (2019) Clinical efficacy of frameless stereotactic radiosurgery in the management of spinal metastases from thyroid carcinoma. Spine (Phila Pa 1976) 44(20):E1188–E1195
Boehling NS, Grosshans DR, Allen PK, McAleer MF, Burton AW, Azeem S, Rhines LD, Chang EL (2012) Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 16(4):379–386
pubmed: 22225488
Faruqi S, Tseng CL, Whyne C, Alghamdi M, Wilson J, Myrehaug S, Soliman H, Lee Y, Maralani P, Yang V, Fisher C, Sahgal A (2018) Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors. Neurosurgery 83(3):314–322
pubmed: 29048517
Ricardi U, Badellino S, Filippi AR (2016) Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res 57(S1):i58–i68
pubmed: 26962198
pmcid: 4990103
Cazzato RL, Bonichon F, Buy X, Godbert Y, de Figuereido BH, Pointillart V, Palussière J (2015) Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer. Eur J Surg Oncol 41(9):1247–1255
pubmed: 26136221
Cazzato RL, Garnon J, Koch G, Shaygi B, Tsoumakidou G, Caudrelier J, Boatta E, Buy X, Palussiere J, Gangi A (2018) Current role of interventional radiology in the management of visceral and bone metastases from thyroid cancer. Gland Surg 7(2):80–88
pubmed: 29770304
pmcid: 5938279
De Vries MM, Persoon AC, Jager PL, Gravendeel J, Plukker JT, Sluiter WJ, Links TP (2008) Embolization therapy of bone metastases from epithelial thyroid carcinoma: effect on symptoms and serum thyroglobulin. Thyroid 18(12):1277–1284
pubmed: 18991486
Smit JW, Vielvoye GJ, Goslings BM (2000) Embolization for vertebral metastases of follicular thyroid carcinoma. J Clin Endocrinol Metab 85(3):989–994
pubmed: 10720028
Son HY, An SY, Kim EY, Ahn SB, Lee BC (2014) Selective embolization for hypervascular metastasis from differentiated thyroid cancer: a case series. J Med Case Rep 8:405
pubmed: 25471328
pmcid: 4289282
Eustatia-Rutten CF, Romijn JA, Guijt MJ, Vielvoye GJ, van den Berg R, Corssmit EP, Pereira AM, Smit JW (2003) Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab 88(7):3184–3189
pubmed: 12843163
Barat M, Tselikas L, de Baère T, Gravel G, Yevich S, Delpla A, Magand N, Louvel G, Hadoux J, Berdelou A, Terroir M, Baudin E, Schlumberger M, Leboulleux S, Deschamps F (2019) Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma. Eur J Radiol 119:108650
pubmed: 31525680
Goldberg SN, Gazelle GS, Mueller PR (2000) Thermal ablation therapy for focal malignancy: a unified approach to underline principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 174(2):323–331
pubmed: 10658699
Murphy KJ, Deramond H (2000) Percutaneous vertebroplasty in benign and malignant disease. Neuroimaging Clin N Am 10(3):535–545
pubmed: 11083017
Kushchayev S, Kushchayeva Y, Theodore N, Preul MC, Clark OH (2010) Percutaneous vertebroplasty for thyroid cancer metastases to the spine. Thyroid 20(5):555–560
pubmed: 20450433
Orgera G, Krokidis M, Rebonato A, Tipaldi MA, Mascagni L, Rossi M (2019) Thyroid skeletal metastasis: pain management with verteblation. BMJ Support Palliat Care 9(1):e2
pubmed: 28424195
Song HJ, Wu CG, Xue YL, Xu YH, Qiu ZL, Luo QY (2012) Percutaneous osteoplasty combined with radioiodine therapy as a treatment for bone metastasis developing after differentiated thyroid carcinoma. Clin Nucl Med 37(6):e129–133
pubmed: 22614210
Habra MA, Song JH, Rietschel P (2015) Outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib versus placebo: results from a phase 3, randomized trial. Abstract 55. Presented at 2015 International Thyroid Congress (Orlando, USA)
Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL (2010) Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95(6):2588–2595
pubmed: 20392874
Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW (2009) Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161(6):923–931
pubmed: 19773371
Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E (2012) Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 167(5):643–650
pubmed: 22918300
Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudette AL, Do Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardière C (2014) Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 170(4):575–582
pubmed: 24424318
Haissaguerre M, Leboulleux S, Bonichon F, Borget I, Chougnet CN, Al Ghuzlan A, Hartl DM, Mirghani H, Deandreis D, Baudin E, Schlumberger M (2012) Impact of molecular targeted therapies in patients with bone metastases of differentiated thyroid carcinoma. Abstract 9. Presented at 2012 American Thyroid Association Congress (Quebec City, Canada)
Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321
pubmed: 15738536
Saad F, Chi K, Fleshner N (2004) The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol 11(5):2376–2382
pubmed: 15576002
Zheng GZ, Chang B, Lin FX, Xie D, Hu QX, Yu GY, Du SX, Li XD (2017) Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. Eur J Cancer Care 26(6):e12541
Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G (2001) Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84(12):1586–1590
pubmed: 11401309
pmcid: 2363684
Orita Y, Sugitani I, Toda K, Manabe J, Fujimoto Y (2011) Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Thyroid 21(1):31–35
pubmed: 21058881
Andrade F, Probstner D, Decnop M, Bulzico D, Momesso D, Corbo R, Vaisman M, Vaisman F (2019) The impact of zoledronic acid and radioactive iodine therapy on morbi-mortality of patients with bone metastases of thyroid cancer derived from follicular cells. Eur Thyroid J 8(1):46–55
pubmed: 30800641
Orita Y, Sugitani I, Takao S, Toda K, Manabe J, Miyata S (2015) Prospective evaluation of zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Ann Surg Oncol 22(12):4008–4013
pubmed: 25762482
Chen F, Pu F (2016) Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat 39(7–8):453–459
pubmed: 27487236
Menshawy A, Mattar O, Abdulkarim A, Kasem S, Nasreldin N, Menshawy E, Mohammed S, Abdel-Maboud M, Gadelkarim M, El Ashal GG, Elgebaly AS (2018) Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 26(4):1029–1038
pubmed: 29387997
Mauceri R, Panzarella V, Morreale I, Campisi G (2019) Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral Maxillofac Surg 48(12):1530–1532
pubmed: 31378564
Wassermann J, Mathy E, Lescaille G, Slim M, Buffet C, Saie C, Braik-Djellas Y, Simon JM, Ménégaux F, Tresallet C, Chami L, Lussey-Lepoutre C, Hervé G, Bernier MO, Spano JP, Leenhardt L (2019) Safety of denosumab in patients with refractory differentiated thyroid cancer and advanced medullary thyroid cancer. J Clin Oncol 37(15_suppl):e17578–e17578
Cao L, Yong-Jing Yang YJ, Diao JD, Zhang XH, Liu YL, Wang BY, Li ZW, Liu SX (2017) Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. Oncotarget 8(52):90308–90314
pubmed: 29163830
pmcid: 5685751